NCT07247279 Epidemiological Study of Treatment Approaches in AChR-Antibody Positive Generalized Myasthenia Gravis in Russia
| NCT ID | NCT07247279 |
| Status | Recruiting |
| Phase | — |
| Sponsor | AstraZeneca |
| Condition | Rare Diseases |
| Study Type | OBSERVATIONAL |
| Enrollment | 450 participants |
| Start Date | 2025-12-23 |
| Primary Completion | 2029-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 450 participants in total. It began in 2025-12-23 with a primary completion date of 2029-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a multicenter, non-interventional, retrospective-prospective, single-arm observational study designed to describe real-world treatment approaches and clinical outcomes among adults with acetylcholine receptor (AChR) antibody-positive generalized myasthenia gravis (gMG) in routine clinical practice in Russia.
Eligibility Criteria
Inclusion Criteria: 1. Adults (≥18 years) diagnosed with generalized MG positive for acetylcholine receptor (AChR) antibodies. 2. Provision of signed and dated written informed consent. Exclusion Criteria: 1. Participants currently enrolled in clinical studies for treatment of gMG. 2. Ocular MG only.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07247279 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Rare Diseases. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07247279 currently recruiting?
Yes, NCT07247279 is actively recruiting participants. Contact the research team at information.center@astrazeneca.com for enrollment information.
Where is the NCT07247279 trial being conducted?
This trial is being conducted at Kazan', Russia, Moscow, Russia, Novosibirsk, Russia, Rostov-on-Don, Russia and 4 additional locations.
Who is sponsoring the NCT07247279 clinical trial?
NCT07247279 is sponsored by AstraZeneca. The trial plans to enroll 450 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.